Table 2.
Adverse Events of Special Interest
| Cohorts 1 and 2 (Single Infusion) | Cohort 3 (Fractionated Infusion) | All Patients | |
|---|---|---|---|
| Acute lymphoblastic leukemia | n = 15 | n = 23 | n = 38 |
| Grade ≥ 3 adverse events, n (%) | 11 (73.3) | 15 (65.2) | 26 (68.4) |
| Severe adverse events, n (%) | 8 (53.3) | 9 (39.1) | 17 (44.7) |
| Grade ≥ 3 CRS, n (%) | 4 (26.7) | 1 (4.3) | 5 (13.2) |
| Grade ≥ 3 ICANS, n (%) | 1 (6.7) | 0 (0.0) | 1 (2.6) |
| Grade ≥ 3 s malignancies, n (%) | 1 (6.7) | 0 (0.0) | 1 (2.6) |
| Non-Hodgkin’s lymphoma | n = 3 | n = 5 | n = 8 |
| Grade ≥ 3 adverse events, n (%) | 3 (100) | 3 (60) | 6 (75) |
| Severe adverse events, n (%) | 3 (100) | 1 (20) | 4 (50) |
| Grade ≥ 3 CRS, n (%) | 1 (33.3) | 1 (20) | 2 (25) |
| Grade ≥ 3 ICANS, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Grade ≥ 3 s malignancies, n (%) | 0 (0) | 0 (0) | 0 (0) |
CRS, cytokine release syndrome; ICANS, immune effector cell-associated neurotoxicity syndrome.